Article
Expanding the options for therapeutic exon skipping as a future treatment for <i>USH2A</i> -associated disease by 3D structural modeling of newly formed hybrid domains
2026-04-28
Abstract excerpt
<h4>ABSTRACT</h4> Usher syndrome, the leading cause of hereditary deaf-blindness affecting approximately 1 in 15,000 individuals worldwide, is currently still untreatable. Antisense oligonucleotide-based exon skipping has shown significant therapeutic promise for USH2A -associated retinal dysfunction. Selection of (combinations of) exons suitable for therapeutic exon skipping within the fibronectin type 3 (FN3)...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- eb06d78d-7dc0-5038-99ab-6a657d19c3f7
- DOI
- 10.64898/2026.04.24.720583
